AI-116

**AI-116** is an Algorae Pharmaceuticals preclinical fixed-dose combination candidate for dementia, including Alzheimer’s disease. It combines cannabidiol with donepezil, an established acetylcholinesterase inhibitor, and was identified using AlgoraeOS before preclinical validation with La Trobe University. Publicly reported in-vitro studies found enhanced neuronal-cell viability versus donepezil alone in neurotoxic dementia-model experiments; the precise combination-specific mechanism remains under investigation. A related international patent application, PCT/AU2024/050791, was published as WO/2025/019898. ([algoraepharma.com](https://algoraepharma.com/algoraeos/dementia/))

Other names

CBD + donepezilCBD + donepezil hydrochloridecannabidiol + donepezilcannabidiol + donepezil hydrochloride